Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The availability of advanced SLED dialysis for critical patients, Plasmapheresis, CRRT machines along with ICCU dialysis complete the centre in every way
Company expects strong organic growth in sales, EBITDA in 2022
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
100% efficacy against severe Covid-19 disease and hospitalizations
Subscribe To Our Newsletter & Stay Updated
